Stock Events

Stock Events

BeiGene 

0
89
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 6Expected
Q1 2026
Q2 2026
Next
0.07
0.09
0.11
0.14
Expected EPS
0.1302011411758254
Actual EPS
N/A

Financials

5.28%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
4.63BRevenue
244.23MNet Income

Analyst Ratings

$329.07Average Price Target
The highest estimate is ⁦352.84⁩.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
89%
Hold
11%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 49B.STU. It's not an investment recommendation.
Microsoft
10
MSFT
NVIDIA
9
NVDA
Pfizer
8
PFE
Taiwan Semiconductor Manufacturing
7
TSM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes in the biotechnology sector focusing on human therapeutics, including oncology, which overlaps with BeiGene's focus on cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology, competing directly with BeiGene's cancer treatment products.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is known for its extensive range of cancer treatments and immunotherapy products, directly competing with BeiGene's oncology focus.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. operates in the biopharmaceutical field, with significant investments in oncology and inflammatory diseases, making it a competitor to BeiGene.
Novartis
NVS
Mkt Cap303.67B
Novartis AG, with a broad portfolio including oncology, directly competes with BeiGene in the development and marketing of cancer therapies.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. is a global biopharmaceutical company with a diverse portfolio that includes oncology, competing with BeiGene in the cancer treatment market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, focuses on oncology among other areas, competing with BeiGene in the cancer treatment space.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC has a strong focus on oncology, respiratory, cardiovascular, and metabolic diseases, making it a direct competitor to BeiGene in the oncology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, Inc. is involved in biopharmaceuticals, focusing on oncology and other areas, which puts it in competition with BeiGene.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company is a global healthcare leader that competes with BeiGene through its oncology division, developing cancer treatments.

About

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Show More
CEO
John V. Oyler
Employees
12000
Country
Switzerland
ISIN
KYG1146Y1017
WKN
000A41ANK

Listings

SA
BR
B1ME34.SA
STU
DE
IJ0.STU
MU
DE
49BA.MU
STU
DE
49BA.STU

0 Comments

Share your thoughts

FAQs

What is BeiGene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange BeiGene stocks are traded under the ticker 49B.STU.
When is the next BeiGene earnings date?▼
BeiGene is going to release the next earnings report on March 31, 2027.
What is BeiGene revenue for the last year?▼
BeiGene revenue for the last year amounts to 4.63B EUR.
What is BeiGene net income for the last year?▼
49B.STU net income for the last year is 244.23M EUR.
How many employees does BeiGene have?▼
As of November 7, 2026, the company has 12,000 employees.
In which sector is BeiGene located?▼
BeiGene operates in the Health & Wellness sector.
When did BeiGene complete a stock split?▼
BeiGene has not had any recent stock splits.
Where is BeiGene headquartered?▼
BeiGene is headquartered in BASEL, Switzerland.